Siegfried Holding AG
SFZN
Rank in Stocks
#4106
Siegfried Holding AG, together with its subsidiaries, engages in contract... Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Share Price
$88.34
Market Cap
$3.87B
Change (1 day)
1.68%
Change (1 year)
-12.97%
Country
CH
Trade Siegfried Holding AG (SFZN)
Category
Healthcare
Earnings for Siegfried Holding AG (SFZN)
Earnings in 2026 TTM: 0
According to Siegfried Holding AG latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Siegfried Holding AG from 2002 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2025 | $262.95M | 21.02% |
| 2024 | $217.28M | 21.51% |
| 2023 | $178.81M | -24.44% |
| 2022 | $236.63M | 70.46% |
| 2021 | $138.82M | 68.39% |
| 2020 | $82.44M | 54.98% |
| 2019 | $53.19M | -25.42% |
| 2018 | $71.32M | 20.14% |
| 2017 | $59.37M | 73.97% |
| 2016 | $34.13M | -7.94% |
| 2015 | $37.07M | 15.84% |
| 2014 | $32.00M | -43.19% |
| 2013 | $56.32M | 239.87% |
| 2012 | $16.57M | 48.10% |
| 2011 | $11.19M | -312.32% |
| 2010 | $-5.27M | -86.49% |
| 2009 | $-39.02M | -52.71% |
| 2008 | $-82.51M | -453.96% |
| 2007 | $23.31M | 6.35% |
| 2006 | $21.92M | -32.38% |
| 2005 | $32.41M | 96.31% |
| 2004 | $16.51M | -65.51% |
| 2003 | $47.87M | -4.28% |
| 2002 | $50.01M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
